Diagnosis and Management of Gastric Neuroendocrine Tumors
Initial Diagnostic Workup
- The European Society of Medical Oncology recommends examining for signs of MEN-1 syndrome and obtaining detailed family history, as gastric NETs can be part of hereditary syndromes 1, 2
- The European Society of Medical Oncology suggests obtaining plasma chromogranin A as a general NET marker 1, 2, 3
- The European Society of Gastrointestinal Endoscopy recommends endoscopic biopsy as mandatory for all suspected gastric NETs 1, 2, 3
Imaging and Staging
- The European Society of Medical Oncology recommends CT or MRI of abdomen for anatomical localization and assessment of liver metastases 1, 2, 6
- The European Society of Medical Oncology suggests somatostatin receptor imaging to detect somatostatin receptor-positive tumors and distant metastases 1, 2, 3
Type Classification and Treatment Algorithm
- The National Comprehensive Cancer Network recommends radical gastrectomy with lymph node dissection for resectable type III gastric NETs 6
- The European Society of Medical Oncology suggests chemotherapy with cisplatin-etoposide for poorly differentiated G3 neuroendocrine carcinomas 6
Management Based on Tumor Size and Grade
- The European Society of Medical Oncology recommends surgical resection with lymphadenectomy for large tumors (>2 cm) or G3 6
Follow-Up and Surveillance
- The European Society of Medical Oncology suggests serial chromogranin A measurements every 3-6 months for G1/G2 tumors 6
- The European Society of Medical Oncology recommends CT or MRI every 3-6 months for NET G1/G2 5, 6
Critical Pitfalls to Avoid
- The European Society of Medical Oncology warns against relying on chromogranin A alone for diagnosis—it can be falsely elevated by proton pump inhibitors, renal failure, and atrophic gastritis 1, 4
- The European Society of Medical Oncology emphasizes the importance of Ki-67 assessment for proper grading and treatment selection 3, 5, 6